Q2 2026 13F · SEC CIK 1882053
Boone Capital Management LLC
Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $427.5M
- Reported positions
- 16
- Top holdings a year, 3 yrs
- +1.9%
- Assets under management
- $963.2M
Boone Capital Management LLC is a hedge fund that reported 16 positions worth $427.5M in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Teleflex Incorporated (TFX, 11.5%), Mirum Pharmaceuticals Inc (MIRM, 11.4%), The Cigna Group (CI, 10.3%). A portfolio copying its top holdings returned 1.9% a year over the last 3 years, against 20.4% for the S&P 500.
Boone Capital Management LLC holdings all 16 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
| Stock | % of 13F value | Share change | Reported value |
|---|---|---|---|
| TFXTeleflex Incorporated | 11.5% | +39.0% | $49.1M |
| MIRMMirum Pharmaceuticals Inc | 11.4% | -1.3% | $48.7M |
| CIThe Cigna Group | 10.3% | +15.8% | $43.9M |
| IONSIonis Pharmaceuticals Inc | 9.6% | +3.9% | $41.2M |
| UNHUnitedhealth Group Inc | 8.6% | +11.9% | $36.9M |
| BMRNBiomarin Pharmaceutical Inc | 7.8% | +6.5% | $33.4M |
| GRDNGuardian Pharmacy Svcs Inc | 7.0% | +12.8% | $29.8M |
| VSTSVestis Corporation | 6.5% | — | $27.6M |
| BBIOBridgebio Pharma Inc | 5.9% | +48.5% | $25.3M |
| PNTGPennant Group Inc | 4.5% | — | $19.1M |
| GLUEMonte Rosa Therapeutics Inc | 3.5% | — | $14.9M |
| KODKodiak Sciences Inc | 3.4% | +34.4% | $14.7M |
| TNGXTango Therapeutics Inc | 3.3% | — | $14.2M |
| KYMRKymera Therapeutics Inc | 3.0% | — | $13.0M |
| CGEMCullinan Therapeutics Inc | 3.0% | — | $12.8M |
| ANLAdlai Nortye Ltd | 0.7% | — | $3.0M |
What Boone Capital Management LLC bought and sold in Q2 2026, against Q1 2026.
New positions
- VSTS Vestis Corporation6.5% of 13F
- PNTG Pennant Group Inc4.5% of 13F
- GLUE Monte Rosa Therapeutics Inc3.5% of 13F
- TNGX Tango Therapeutics Inc3.3% of 13F
- KYMR Kymera Therapeutics Inc3.0% of 13F
- CGEM Cullinan Therapeutics Inc3.0% of 13F
- ANL Adlai Nortye Ltd0.7% of 13F
Added to
- BBIO Bridgebio Pharma Inc+48.5% shares
- TFX Teleflex Incorporated+39.0% shares
- KOD Kodiak Sciences Inc+34.4% shares
- CI The Cigna Group+15.8% shares
- GRDN Guardian Pharmacy Svcs Inc+12.8% shares
- UNH Unitedhealth Group Inc+11.9% shares
- BMRN Biomarin Pharmaceutical Inc+6.5% shares
Reduced
No position shrank by more than 5%.
Sold out
- MDT Medtronic PLCwas 10.6%
- AZN Astrazeneca PLCwas 6.7%
- AVNS Avanos Med Incwas 5.1%
- TENX Tenax Therapeutics Incwas 1.0%
Share counts compared with the Q1 2026 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- +16.6% /yr
- S&P 500 +20.1%
- 3 years
- +1.9% /yr
- S&P 500 +20.4%
- 5 years
- —
A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $427.5M | 16 |
| Q1 2026 | $326.4M | 13 |
| Q4 2025 | $318.6M | 15 |
| Q3 2025 | $305.0M | 16 |
| Q2 2025 | $233.2M | 11 |
| Q1 2025 | $293.8M | 12 |
| Q4 2024 | $296.5M | 13 |
| Q3 2024 | $385.8M | 17 |
| Q2 2024 | $383.4M | 19 |
| Q1 2024 | $494.4M | 21 |
| Q4 2023 | $428.4M | 21 |
| Q3 2023 | $317.0M | 13 |
Questions about Boone Capital Management LLC's portfolio
What stocks does Boone Capital Management LLC own?
Boone Capital Management LLC's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 16 positions worth $427.5M. The largest are Teleflex Incorporated (TFX) at 11.5%, Mirum Pharmaceuticals Inc (MIRM) at 11.4%, The Cigna Group (CI) at 10.3%, Ionis Pharmaceuticals Inc (IONS) at 9.6% and Unitedhealth Group Inc (UNH) at 8.6%.
What did Boone Capital Management LLC buy last quarter?
In Q2 2026, Boone Capital Management LLC added a new position in Vestis Corporation (VSTS), a new position in Pennant Group Inc (PNTG), a new position in Monte Rosa Therapeutics Inc (GLUE), a new position in Tango Therapeutics Inc (TNGX), a new position in Kymera Therapeutics Inc (KYMR), Bridgebio Pharma Inc (BBIO) (+48.5% shares), Teleflex Incorporated (TFX) (+39.0% shares) and Kodiak Sciences Inc (KOD) (+34.4% shares), compared with its Q1 2026 filing.
What did Boone Capital Management LLC sell last quarter?
In Q2 2026, Boone Capital Management LLC sold all of Medtronic PLC (MDT), sold all of Astrazeneca PLC (AZN), sold all of Avanos Med Inc (AVNS) and sold all of Tenax Therapeutics Inc (TENX), compared with its Q1 2026 filing.
How has Boone Capital Management LLC's portfolio performed?
A portfolio copying Boone Capital Management LLC's 20 largest 13F holdings each quarter, from the day each filing was public, returned +1.9% a year over the last 3 years, against +20.4% for the S&P 500. Over 1 year: +16.6% against +20.1%.
When is Boone Capital Management LLC's next 13F filing due?
13F filings are due 45 days after each quarter ends. Boone Capital Management LLC's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.
How much money does Boone Capital Management LLC manage?
Boone Capital Management LLC reported $963.2M of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $427.5M.